Healthcare provider profile · identity verified

Scott Michael Meyer, PA

Physician Assistant · ALTOONA, IA · NPI 1043270507

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	392	111
Simvastatin	Simvastatin	364	101
Levothyroxine Sodium	Levothyroxine Sodium	354	86
Lisinopril	Lisinopril	286	81
Omeprazole	Omeprazole	225	60
Metformin Hcl Er	Metformin Hcl	197	52
Amlodipine Besylate	Amlodipine Besylate	183	51
Escitalopram Oxalate	Escitalopram Oxalate	149	34
Metoprolol Succinate	Metoprolol Succinate	149	41
Losartan Potassium	Losartan Potassium	147	46
Tamsulosin Hcl	Tamsulosin Hcl	141	46
Rosuvastatin Calcium	Rosuvastatin Calcium	133	42
Citalopram Hbr	Citalopram Hydrobromide	128	33
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	125	37
Allopurinol	Allopurinol	119	33
Metformin Hcl	Metformin Hcl	117	32
Glipizide Er	Glipizide	106	27
Hydrochlorothiazide	Hydrochlorothiazide	99	30
Furosemide	Furosemide	88	27
Pantoprazole Sodium	Pantoprazole Sodium	87	30
Glipizide	Glipizide	83	17
Potassium Chloride	Potassium Chloride	82	20
Montelukast Sodium	Montelukast Sodium	80	21
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	79	23
Pravastatin Sodium	Pravastatin Sodium	79	21
Albuterol Sulfate Hfa	Albuterol Sulfate	77	29
Gabapentin	Gabapentin	77	26
Metoprolol Tartrate	Metoprolol Tartrate	76	21
Meloxicam	Meloxicam	75	24
Tramadol Hcl	Tramadol Hcl	75	28
Fluoxetine Hcl	Fluoxetine Hcl	72	16
Sertraline Hcl	Sertraline Hcl	72	23
Lamotrigine	Lamotrigine	71	suppressed
Tizanidine Hcl	Tizanidine Hcl	69	36
Zolpidem Tartrate	Zolpidem Tartrate	68	19
Jardiance	Empagliflozin	67	15
Fluticasone Propionate	Fluticasone Propionate	65	23
Trazodone Hcl	Trazodone Hcl	65	19
Alprazolam	Alprazolam	64	20
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	64	20
Bupropion Xl	Bupropion Hcl	61	16
Alendronate Sodium	Alendronate Sodium	58	12
Topiramate	Topiramate	56	suppressed
Atenolol	Atenolol	53	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	48	44
Azithromycin	Azithromycin	47	40
Ozempic	Semaglutide	47	14
Clonazepam	Clonazepam	46	13
Methylprednisolone	Methylprednisolone	45	40
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	41	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	40	11
Mirtazapine	Mirtazapine	40	suppressed
Tresiba Flextouch U-100	Insulin Degludec	39	suppressed
Lactulose	Lactulose	37	suppressed
Rybelsus	Semaglutide	37	suppressed
Duloxetine Hcl	Duloxetine Hcl	36	suppressed
Famotidine	Famotidine	36	12
Fenofibrate	Fenofibrate	36	suppressed
Cephalexin	Cephalexin	35	22
Oxybutynin Chloride Er	Oxybutynin Chloride	35	suppressed
Amoxicillin	Amoxicillin	34	28
Benazepril Hcl	Benazepril Hcl	34	suppressed
Warfarin Sodium	Warfarin Sodium	34	suppressed
Clopidogrel	Clopidogrel Bisulfate	33	11
Triamcinolone Acetonide	Triamcinolone Acetonide	31	23
Levetiracetam	Levetiracetam	30	suppressed
Prednisone	Prednisone	30	28
Memantine Hcl	Memantine Hcl	27	suppressed
Nystatin	Nystatin	27	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	27	suppressed
Carvedilol	Carvedilol	26	suppressed
Divalproex Sodium	Divalproex Sodium	26	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	26	suppressed
Rufinamide	Rufinamide	26	suppressed
Ezetimibe	Ezetimibe	25	suppressed
Eliquis	Apixaban	22	13
Xtampza Er	Oxycodone Myristate	22	suppressed
Chlorthalidone	Chlorthalidone	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	12
Diclofenac Sodium	Diclofenac Sodium	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Finasteride	Finasteride	21	suppressed
Glimepiride	Glimepiride	21	suppressed
Spironolactone	Spironolactone	20	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	19	suppressed
Cefuroxime	Cefuroxime Axetil	19	17
Insulin Lispro Kwikpen U-100	Insulin Lispro	19	suppressed
Nabumetone	Nabumetone	19	suppressed
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	15
Donepezil Hcl	Donepezil Hcl	16	suppressed
Hydralazine Hcl	Hydralazine Hcl	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Primidone	Primidone	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Fluconazole	Fluconazole	14	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Risperidone	Risperidone	14	suppressed
Celecoxib	Celecoxib	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Valacyclovir	Valacyclovir Hcl	13	suppressed
Vilazodone Hcl	Vilazodone Hcl	13	suppressed
Azelastine Hcl	Azelastine Hcl	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Hydroxyurea	Hydroxyurea	12	suppressed
Labetalol Hcl	Labetalol Hcl	12	suppressed
Naproxen	Naproxen	12	suppressed
Propafenone Hcl	Propafenone Hcl	12	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	11	suppressed
Bumetanide	Bumetanide	11	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Carbamazepine	Carbamazepine	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error